Resmed (RSMDF) Current Deferred Revenue (2010 - 2026)

Resmed (RSMDF) has reported Current Deferred Revenue for 17 consecutive years, with $162.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue fell 1.88% year-over-year to $162.9 million; the trailing twelve-month figure through Jun 2026 stood at $162.9 million (down 1.88% YoY), and the FY2026 full-year result was $162.9 million, down 1.88% from the prior year.
• Current Deferred Revenue fell to $162.9 million in Q2 2026 per RSMDF's latest filing, from $179.3 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $179.3 million in Q1 2026 and bottomed at $108.2 million in Q3 2022.
• Historically, Current Deferred Revenue has averaged $148.2 million across 5 years, with a median of $151.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue retreated 3.85% in 2022, then soared 35.61% in 2023.
• Over 5 years, Current Deferred Revenue stood at $133.9 million in 2022, then grew by 11.19% to $148.9 million in 2023, then rose by 5.11% to $156.5 million in 2024, then gained by 12.49% to $176.0 million in 2025, then fell by 7.46% to $162.9 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $162.9 million, $179.3 million, and $176.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.